[Acinetobacter, a nosocomial pathogen. Contribution of experimental models].
BACKGROUND
The increasing importance of Acinetobacter as a nosocomial pathogen responsible for outbreaks in intensive care units has been pointed out for twenty years. Today Acinetobacter infections are essentially pneumonia in patients under mechanical ventilation.
Most clinical isolates are resistant to b-lactam antibiotics as well as to other drugs. Animal models represent an essential step between in vivo testing an<d clinical studies, necessary to understand physiopathology, pharmacology and efficacy of therapy. The virulence of clinical isolates of Acinetobacter spp has been studied in a mouse model of systemic infection. Pharmacological studies and efficacy of antibiotics have been studied in a mouse model of Acinetobacter pneumonia.
The majority of strains are multi-resistant to antibiotics and the infections they cause are difficult to treat. Isolated or combined Sulbactam has often been used with success.
Joly-Guillou
M L
ML
Hôpital Louis-Mourier, service de microbiologie, 178, rue des Renouilliers, 92701 Colombes. marie-laure.joly-guillou@lmr.ap-hop-paris.fr
Hidri
N
N
Wolff
M
M
D000150:Acinetobacter / Q000472:pathogenicity*; D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000635:transmission; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection; D004196:Disease Outbreaks; D018432:Drug Resistance, Multiple; D006801:Humans; D007362:Intensive Care Units; D008962:Models, Theoretical; D018410:Pneumonia, Bacterial; D012121:Respiration, Artificial / Q000009:adverse effects; D014774:Virulence
D000900:Anti-Bacterial Agents